Cargando…
Engineered Phage-Based Cancer Vaccines: Current Advances and Future Directions
Bacteriophages have emerged as versatile tools in the field of bioengineering, with enormous potential in tissue engineering, vaccine development, and immunotherapy. The genetic makeup of phages can be harnessed for the development of novel DNA vaccines and antigen display systems, as they can provi...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10222954/ https://www.ncbi.nlm.nih.gov/pubmed/37243023 http://dx.doi.org/10.3390/vaccines11050919 |
_version_ | 1785049823865470976 |
---|---|
author | Ragothaman, Murali Yoo, So Young |
author_facet | Ragothaman, Murali Yoo, So Young |
author_sort | Ragothaman, Murali |
collection | PubMed |
description | Bacteriophages have emerged as versatile tools in the field of bioengineering, with enormous potential in tissue engineering, vaccine development, and immunotherapy. The genetic makeup of phages can be harnessed for the development of novel DNA vaccines and antigen display systems, as they can provide a highly organized and repetitive presentation of antigens to immune cells. Bacteriophages have opened new possibilities for the targeting of specific molecular determinants of cancer cells. Phages can be used as anticancer agents and carriers of imaging molecules and therapeutics. In this review, we explored the role of bacteriophages and bacteriophage engineering in targeted cancer therapy. The question of how the engineered bacteriophages can interact with the biological and immunological systems is emphasized to comprehend the underlying mechanism of phage use in cancer immunotherapy. The effectiveness of phage display technology in identifying high-affinity ligands for substrates, such as cancer cells and tumor-associated molecules, and the emerging field of phage engineering and its potential in the development of effective cancer treatments are discussed. We also highlight phage usage in clinical trials as well as the related patents. This review provides a new insight into engineered phage-based cancer vaccines. |
format | Online Article Text |
id | pubmed-10222954 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-102229542023-05-28 Engineered Phage-Based Cancer Vaccines: Current Advances and Future Directions Ragothaman, Murali Yoo, So Young Vaccines (Basel) Review Bacteriophages have emerged as versatile tools in the field of bioengineering, with enormous potential in tissue engineering, vaccine development, and immunotherapy. The genetic makeup of phages can be harnessed for the development of novel DNA vaccines and antigen display systems, as they can provide a highly organized and repetitive presentation of antigens to immune cells. Bacteriophages have opened new possibilities for the targeting of specific molecular determinants of cancer cells. Phages can be used as anticancer agents and carriers of imaging molecules and therapeutics. In this review, we explored the role of bacteriophages and bacteriophage engineering in targeted cancer therapy. The question of how the engineered bacteriophages can interact with the biological and immunological systems is emphasized to comprehend the underlying mechanism of phage use in cancer immunotherapy. The effectiveness of phage display technology in identifying high-affinity ligands for substrates, such as cancer cells and tumor-associated molecules, and the emerging field of phage engineering and its potential in the development of effective cancer treatments are discussed. We also highlight phage usage in clinical trials as well as the related patents. This review provides a new insight into engineered phage-based cancer vaccines. MDPI 2023-04-29 /pmc/articles/PMC10222954/ /pubmed/37243023 http://dx.doi.org/10.3390/vaccines11050919 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Ragothaman, Murali Yoo, So Young Engineered Phage-Based Cancer Vaccines: Current Advances and Future Directions |
title | Engineered Phage-Based Cancer Vaccines: Current Advances and Future Directions |
title_full | Engineered Phage-Based Cancer Vaccines: Current Advances and Future Directions |
title_fullStr | Engineered Phage-Based Cancer Vaccines: Current Advances and Future Directions |
title_full_unstemmed | Engineered Phage-Based Cancer Vaccines: Current Advances and Future Directions |
title_short | Engineered Phage-Based Cancer Vaccines: Current Advances and Future Directions |
title_sort | engineered phage-based cancer vaccines: current advances and future directions |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10222954/ https://www.ncbi.nlm.nih.gov/pubmed/37243023 http://dx.doi.org/10.3390/vaccines11050919 |
work_keys_str_mv | AT ragothamanmurali engineeredphagebasedcancervaccinescurrentadvancesandfuturedirections AT yoosoyoung engineeredphagebasedcancervaccinescurrentadvancesandfuturedirections |